Graft Versus Host Disease (GvHD) Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Sep 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a high dose of chemotherapy, the bone marrow is received by patient the donor through infusion, which helps with resumption of blood cells production. Graft versus host disease occurs when particular type of white blood cells are not compatible with the existing cell type and thus, leads to an attack by the transplanted cells on the recipient body. It is a difficult procedure to diagnose the agents and the compatibility during the transplant. Symptoms of Gvhd are usually not too severe, though in some cases it can be fatal. During autologous transplant, the patient is free from such complications. Also, prior to the transplant, cells of the donor and recipient are closely screened and matched so as to avoid Gvhd by ensuring the closest possible match.

Graft Versus Host Disease Market Taxonomy:

By Disease Type

  • Acute graft vs. host disease (aGvHD)
  • Chronic graft vs. host disease (cGvHD)

By Product Type

  • Monoclonal antibodies
  • mTOR inhibitors
  • Tyrosine kinase inhibitors
  • Thalidomide
  • Etanercept

High investment in research and development is expected to favor growth of the graft versus host disease market:

In the recent past, the graft versus host disease market has significantly evolved with the introduction of biological and patented small molecule immunosuppressive therapies and been added to the treatment regime. The current research and development programs in Gvhd are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. R&D strategies in Gvhd are characterized by an increasing trend towards maintaining appropriate prophylactic regimens and inhibiting proliferation and activation of T-cell. Such regimens in Gvhd are tailored to conditioning and transplant type and used for hematopoietic stem cell transplantation (HSCT). However, there is significant possibility of risk of opportunistic infection during this process.

However, most of the ventures in research and development process, including academically running clinical studies regarding targeting niche subgroup under Gvhd such as steroid refractory aGVHD and cGVHD, are key R&D strategies in the GVHD pipeline, with around 30 products in the pipeline targeting such populations. Extensive research and development activities are expected to favor growth of the graft versus host disease industry in the near future.

Large unmet needs in the Gvhd management are one of the most important factors fueling growth of the graft versus host disease market. At present there are very few or no guidelines for management of graft versus host disease that can precisely maintain the data for the large population suffering from Gvhd, though certain recommendations for such therapies are in place.

Lack of regulatory guidelines pegs back growth of graft versus host disease market

The disease is orphan in nature, which can be one of the important factors affecting the lack of guidelines and treatment regimes. Lack of randomized clinical trials is another factor that contributes towards non-popularity of Gvhd due to the use of variable clinical trial endpoints conducted studies till date. This has resulted in inappropriate clinical evidences, which are not comparable and not directly applicable to all Gvhd patient groups. However, advancements in the process of early detection of symptoms is projected to support growth of the graft versus host disease market in the near future.

Major research universities in the GvHD market are engaged in research and development processes to further enhance the outcomes of the therapy. For instance, research conducted by the University Of Michigan, in 2017, revised the understanding regarding the graft vs. host disease origins, which can offer new direction for potential therapy in the near future.

Market players in the GvHD market focusing on inorganic growth strategies to strength product portfolio

The global graft versus host disease market is competitive and fragmented. Major players in the market are developing novel products and spending significantly in research and development, along with major acquisitions and collaborations to achieve competitive edge over their counterparts. For instance, Kalytera Therapeutics, Inc. acquired Talent Biotechs Ltd. – an Israeli-based developer of proprietary cannabidiol therapeutic. This is expected to favor the increase in company’s product portfolio. Some of the key players in the Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.

Key Developments

  1. Major companies are focused on various growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio. For instance, in May 2019, Incyte Corporation, a U.S.-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for ‘Jakafi’, a drug indicated for the treatment of steroid-refractory acute GVHD for adults and pediatric patients aged 12 years and above.
  2. Key players in the market are focused in various business strategies such as gaining product approval from regulatory authorities, in order to gain competitive edge in the market. For instance, in November 2017, Merck & Co., Inc., a pharmaceutical company, received the U.S. FDA approval for PREVYMIS, which is a tablet for oral use and injection for infusion. PREVYMIS is indicated for the patients suffering from GVHD.
  3. Key players in the market are focused in various business strategies such as gaining product approval from regulatory authorities, in order to gain competitive edge in the market. For instance, in August 2017, Pharmacyclics LLC, a biopharmaceutical company, received the U.S. FDA approval for Imbruvica (ibrutinib) drug, which will be used for adult patients with chronic graft versus host disease.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.